BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
BioNTech (NASDAQ:BNTX) shares traded higher on Tuesday after Jefferies upgraded the German COVID-19 vaccine maker to Buy from ...
2d
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE (BNTX – Research Report), ...
BioNTech released new mid-stage data for its lung cancer drug, BNT327, at the cancer conference ESMO. The results showed that BNT327 reached a 57.8% confirmed objective response rate in patients with ...
Jefferies upgraded BioNTech (BNTX) to Buy from Hold with a price target of $150, up from $96. Following Summit Therapeutics' ...
Evercore ISI upgraded Sprouts Farmers Market (SFM) to Outperform from In Line with a price target of $120, up from $96. The ...
Notably, we dosed the first patient in a trial evaluating the combination of the TROP2 antibody-drug conjugate BNT325/DB-1305 and the PD-L1-VEGF-A bispecific BNT327/PM8002, aiming to harness the ...
The updates included data on multiple drug candidates, such as BNT327 (PD-L1xVEGF), BNT113 (HPV16+ FixVac), BNT211 (CLDN6+ CAR-T), and BNT316 (CTLA-4). The spotlight was on BNT327, particularly after ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback